Lumida
/FATE
⌘K
Fate Therapeutics Inc

Fate Therapeutics Inc

FATE
$2.78USD↑+1.83%+0.05 today

MARKET CAP

324.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$1
$3

AI Summary

Stalk
Buy NowMedium

Stock is in a Stage 2 uptrend medium-term bullish environment, showing a pullback into rising EMAs that have held support, offering a timely buy opportunity despite a Bullish Exhaustion pattern that signals possible short-term fatigue.

  • ↑FDA cleared FT839 IND, enabling late-2026 basket trial in multiple autoimmune diseases.
  • ↑FT819 Phase I data: all four lupus patients hit rCRISS ≥25 with mRSS improvement.
  • ↓Q2 ’23 net loss of $52.8M and Q1 ’24 revenue plunged to $1.9M.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer and autoimmune diseases using its proprietary induced pluripotent stem cell (iPSC) technology. It is currently navigating a strategic transition following the notable unwinding of its collaboration with Janssen, aiming to solidify its pipeline in advanced cellular therapies, especially targeting significant unmet medical needs in oncology and autoimmunity.

Bull says

  • ↑FDA cleared FT839 IND, enabling late-2026 basket trial in multiple autoimmune diseases.
  • ↑FT819 Phase I data: all four lupus patients hit rCRISS ≥25 with mRSS improvement.
  • ↑Q1 ’24 cash reserves of $391M fund operations and R&D into late 2026.
  • ↑Off-the-shelf iPSC-derived CAR-T platform offers potential cost and accessibility advantages.
  • ↑13F hedge fund ownership at 0.57 indicates institutional support for upside.
  • ↑Encouraging clinical data and regulatory tailwinds support future pipeline catalysts.

Bear says

  • ↓Q2 ’23 net loss of $52.8M and Q1 ’24 revenue plunged to $1.9M.
  • ↓Negative earnings yield and unprofitable operations stress financial sustainability.
  • ↓Over 10 autologous CAR-T programs intensify competition in oncology and autoimmunity.
  • ↓Dose-escalation trial enrollment challenges threaten timely clinical data readouts.
  • ↓Regulatory pathway for FT522 remains uncertain, risking delayed approvals.
  • ↓R&D spend of $32.1M and G&A up 16% to $20.9M accelerate cash burn.

Investment themes with FATE

Biotech↑ +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Others↑ +0.32%

Miscellaneous or uncategorized companies

ATAI · SVIX · SVXY

Earnings Call · Q1 2023 · Mgmt. Guidance

Updated 07-14-2026bullish

Transcript signals

Bull points

  • We remain confident that our proprietary IPSC product platform is uniquely suited to create highly differentiated product candidates that incorporate novel synthetic controls of cell function, deliver multiple mechanisms of action to maximize clinical efficacy, and maintain a safety profile that permits broad accessibility to patients, including in a community-based setting.
  • We believe the off-the-shelf combination of FT576 and CD38-targeted monoclonal antibody therapy may offer an attractive and differentiated therapeutic proposition by enabling antibody-dependent cellular cytotoxicity, multi-antigen targeting of myeloma cells, and patient reach into community-based settings.
  • We have previously reported interim Phase I clinical data of the combination from the first single dose treatment cohort at 100 million cells, which showed a favorable safety profile and clinical activity.

Bear points

  • The quarter was marked by the termination of our collaboration with Janssen, where we completed an orderly wind down of all collaboration activities.
  • we decided to discontinue further development of our FT516, FT596, FT538, and FT536 NK cell programs.
  • As a consequence of determination of our Janssen collaboration and our strategic pipeline prioritization, we significantly reduced our workforce.
Read full transcript analysis ›